BIOCON,India's largest and fully integrated, innovation led Biopharmaceutical Company and QUARK pharmaceutical company a leader in thediscovery and development of novel RNA-i based therapeuticsannounced today the randomization of the first patient in India in the pivotal global phase II/III study of QPI-1007, a novel siRNA (small interfering RNA) drug candidate for ocular neuroprotection. The Drug Controller General of Indiapermitted BIOCON and QUARKpharmaceutical to continue with their study, Indi